Stryker Co. (NYSE:SYK) Shares Sold by Wealthspire Advisors LLC

Wealthspire Advisors LLC cut its holdings in shares of Stryker Co. (NYSE:SYK) by 10.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 6,140 shares of the medical technology company’s stock after selling 720 shares during the period. Wealthspire Advisors LLC’s holdings in Stryker were worth $2,211,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker during the 4th quarter worth approximately $30,000. Darwin Wealth Management LLC acquired a new stake in Stryker during the 3rd quarter worth approximately $36,000. Activest Wealth Management acquired a new stake in Stryker during the 4th quarter worth approximately $36,000. Finally, Crews Bank & Trust acquired a new stake in Stryker during the 4th quarter worth approximately $39,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 1.0 %

NYSE SYK opened at $382.59 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $145.99 billion, a PE ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm’s fifty day moving average is $378.07 and its two-hundred day moving average is $369.34.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm earned $3.46 EPS. Analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on SYK shares. BTIG Research raised their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Truist Financial raised their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Citigroup raised their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, The Goldman Sachs Group raised their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.